Report Analyzes Dynamics of Product Usage, Physicians’ Treatment Patterns and Patient Population
EXTON, Pa.--(BUSINESS WIRE)-- Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, will release analysis of the treatment of complicated skin and skin structure infections (cSSSIs) in Europe. Complicated skin and skin structure infections are a key driver of the hospital antibiotic market, and are often complicated by pre-existing complications and conditions, such as diabetes mellitus. Moreover, treatment of cSSSIs due to antibiotic-drug resistant pathogens, specifically methicillin-resistant Staphylococcus aureus (MRSA) is an important aspect of the European hospital antibiotic market because MRSA infections drive the uptake of narrow-spectrum therapies, such as vancomycin, Sanofi-Aventis’s Targocid, Pfizer’s Zyvox and Cubist/Novartis’s Cubicin.
The report, Hospital Insight Series: Complicated Skin and Skin Structure Infections (Europe), uses clinical audit data and primary research with infectious disease specialists to understand the dynamics of product usage and physicians’ treatment patterns. The report also provides segmentation of cSSSI patient population, identifies rates of treatment failure and discontinuation by drug and provides insight into why physicians have changed their treatment approach to cSSSIs in recent years.
“For pharmaceutical companies manufacturing therapies to treat complicated skin and skin structure infections, this analysis is valuable for identifying key prescribers and understanding physicians’ therapy preferences and factors that influence both current and future prescribing patterns,” said AMR Analyst Brenda Perez-Cheeks, Ph.D. “Our primary research also reveals insights into infectious disease physicians’ receptivity to novel and emerging therapies, as well as unmet needs in the complicated skin and skin structure infections market.”
About AMR
AMR (www.AMR-data.com) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
CONTACT:
Decision Resources
Lisa Osgood, 781-993-2606
[email protected]
or
Decision Resources Group
Christopher Comfort, 781-993-2597
[email protected]
KEYWORDS: United States North America Pennsylvania
INDUSTRY KEYWORDS: Health Hospitals Infectious Diseases Pharmaceutical General Health
MEDIA:
| Logo |